SCHEMBL410072

SCHEMBL410072

COc1cc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)ccc1O

nearest known ligand 0.84

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.84
KCNA5 P22460 6/20 0.83
SCN5A Q14524 6/20 0.83
KCND2 Q9NZV8 5/20 0.83
KCNH2 Q12809 1/20 0.83
TAAR1 Q96RJ0 2/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
TMEM97 Q5BJF2 2/20 0.41
SIGMAR1 Q99720 2/20 0.41
PTPN1 P18031 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TRPV6 Q9H1D0 1/20 0.39
PDE4B Q07343 1/20 0.39
ADRB2 P07550 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327983 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL4603469 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12296102 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12122779 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL13097960 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL14390503 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL14851637 1.00 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2
Hydrochloric Acid SCHEMBL4976420 0.99 KCNA5 (0.85) SLC6A4KCNA5SCN5AKCND2KCNH2
Hydrochloric Acid SCHEMBL3029532 0.99 KCNA5 (0.85) SLC6A4KCNA5SCN5AKCND2KCNH2
SCHEMBL12327948 0.92 SLC6A4 (0.84) SLC6A4KCNA5SCN5AKCND2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100217014-A1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2010-08-26 US claimed
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2007-01-18 US claimed
US-8692002-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2014-04-08 US disclosed
US-8618311-B2 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2013-12-31 US disclosed
EP-1915340-B1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP (CA) 2013-08-07 EP disclosed
EP-1915340-B1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP (CA) 2013-08-07 EP disclosed
US-20130090483-A1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2013-04-11 US disclosed
US-20130090483-A1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2013-04-11 US disclosed
US-20130090483-A1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2013-04-11 US disclosed
US-8344162-B2 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2013-01-01 US disclosed
US-8344162-B2 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2013-01-01 US disclosed
US-20090105256-A1 PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2009-04-23 US disclosed
EP-1915340-A2 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS Cardiome Pharma Corp. (CA) 2008-04-30 EP disclosed
US-20080021005-A1 Pegylated Ion Channel Modulating Compounds CARDIOME PHARMA CORP. (CA) 2008-01-24 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same CARDIOME PHARMA CORP. (CA) 2007-04-19 US disclosed
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2007-01-18 US disclosed
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2007-01-18 US disclosed
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2007-01-18 US disclosed
WO-2006138673-A2 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021005-A1 Pegylated Ion Channel Modulating Compounds KCNN3, KCNN2, KCNN1 SLC6A4 247/4885KCNA5 30/4885SCN5A 56/4885
US-20070088075-A1 Deuterated aminocyclohexyl ether compounds and processes for preparing same DDC, HDHD5, DDT SLC6A4 2668/4885KCNA5 2363/4885SCN5A 4208/4885
US-20090105256-A1 PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CACNA1B, CACNA1F, KCNN2 SLC6A4 231/4885KCNA5 48/4885SCN5A 37/4885
US-20070015924-A1 Synthetic processes for the preparation of aminocyclohexyl ether compounds CYP2D6, CYP3A43, CYP2F1 SLC6A4 919/4885KCNA5 56/4885SCN5A 39/4885
US-20130090483-A1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CYP2D6, CYP3A43, CYP2F1 SLC6A4 919/4885KCNA5 56/4885SCN5A 39/4885
US-20100217014-A1 SYNTHETIC PROCESSES FOR THE PREPARATION OF AMINOCYCLOHEXYL ETHER COMPOUNDS CYP2D6, CYP3A43, CYP2F1 SLC6A4 919/4885KCNA5 56/4885SCN5A 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.